Aptar Pharma recently organized a scientific roundtable in Paris, with the theme “Inhaler Adherence, Exploring Key Factors”. Aptar Pharma roundtables have been organized regularly for a number of years, and provide a platform for experts in a specific scientific discipline to share knowledge and discuss current issues and avenues for future development.
Inhaler adherence in the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD) by pressurized metered dose inhalers (pMDIs) and dry powder inhalers is a very real issue. Studies have shown that up to 50 percent of patients who use inhalers for asthma do not adhere to their prescriptions, and 50 percent of patients who use pMDIs do not use them correctly. The result of this is poor disease control and increased healthcare costs.
A number of key opinion leaders in inhaler adherence from France and the UK were invited to the roundtable. Discussions identified a number of issues that impact non-adherence and looked at ways of addressing these issues, in both the short and long-term.
The participants looked at current guidance for therapy/inhaler prescribing. Although detailed guidance about therapies exists, prescribing an inhaler also depends on the patient’s capabilities. It was agreed that selecting the right type of inhaler for the patient is at least as important as selecting the therapy. The participants also discussed issues raised by both healthcare professionals and patients relating to inhalers, and possible ways of making inhalers more adherence-friendly. Looking to the future, the participants saw promise for improved adherence in active monitoring and feedback, using smart devices. A new generation of e-devices will potentially be able to communicate with future tele-health systems.
As a result of the roundtable, Aptar Pharma prepared a scientific publication entitled “Inhaler Adherence, Exploring Key Factors”. This reprint is now available on the Aptar Pharma website.